AstraZeneca’s Lung Cancer Drug Secures China Approval (AZN) | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 27 March, 2017 by The TZ Newswire Staff

AstraZeneca’s Lung Cancer Drug Secures China Approval (AZN)

Tagrisso becomes first drug from AstraZeneca to be approved under China’s new Priority Review pathway.

See also
- Next Article Market Extra: ‘Trump disappointment trade is now in full swing’ — analysts on global stock selloff
- Previous Article Peter Morici: Immigration reform could be the win that Trump and the economy need
Editorial Calender

March 2017

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Feb Apr »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar